Biological Dynamics appoints Zach Miller to its Board of Directors

– USA, CA –  Biological Dynamics, Inc., an emerging growth life sciences company, today announced the appointment of Zach Miller to its Board of Directors.

“Zach’s deep expertise in healthcare investing and strong track record in building successful companies will be invaluable to our team as we work toward our mission to provide tools for earlier cancer detection. Zach will play an important role in supporting the commercialization of our ExoVerita exosome-isolation platform and ExoVita Pancreas assay, which we believe will make a meaningful impact for millions of patients worldwide,” said CEO, Dr. Paul Billings.

About Zach Miller

Zach Miller is the founder and managing partner of Parian Global Management, a healthcare-focused investment partnership established in 2018. He has extensive experience in healthcare investing and previously worked on finance teams at Slate Path Capital and Bain Capital, where he focused on medical and information technology companies. Miller holds a bachelor’s degree, summa cum laude, from Williams College and a master’s degree in philosophy with distinction from Worcester College, Oxford University.

“I am honored to join Biological Dynamics’ Board of Directors and look forward to supporting the Company’s mission to provide groundbreaking diagnostic solutions for early disease detection,” said Zach Miller. “I believe in the potential of the Company’s technology to revolutionize how we detect and treat diseases.”

About Biological Dynamics

Biological Dynamics, Inc., is committed to improving global health outcomes by detecting early detection of diseases. Its proprietary exosome-isolation ExoVerita platform, currently used by the company and research customers, simplifies the isolation of extracellular vesicles, enabling multi-omic applications. Biological Dynamics recently initiated its ExoLuminate study, a clinical trial to demonstrate the effectiveness of its ExoVita Pancreas assay for early-stage detection of pancreatic cancer. The assay is a lab-developed test validated in the Company’s College of American Pathologists accredited, CLIA-certified clinical laboratory in San Diego.


- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.